Cited by 3,066Diabetes Treatment and ManagementDiabetes Management and ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 65 of the 68 references it cites were found in a registry or an index.

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

Open access

Inzucchi, Silvio E., Bergenstal, Richard M., Buse, John B., Diamant, Michaela, Ferrannini, Ele, Nauck, Michael, Peters, Anne L., Tsapas, Apostolos, Wender, Richard, Matthews, David R.·2015·Diabetes Care

DOI 10.2337/dc14-2441

Open this paper in CoChat — free account

Abstract

In 2012, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a position statement on the management of hyperglycemia in patients with type 2 diabetes (1,2). This was needed because of an increasing array of antihyperglycemic drugs and growing uncertainty regarding their proper selection and sequence. Because of a paucity of comparative effectiveness research on long-term treatment outcomes with many of these medications, the 2012 publication was less prescriptive than prior consensus reports. We previously described the need to individualize both treatment targets and treatment strategies, with an emphasis on patient-centered care and shared decision making, and this continues to be our position, although there are now more head-to-head trials that show slight variance between agents with regard to glucose-lowering effects. Nevertheless, these differences are often small and would be unlikely to reflect any definite differential effect in an individual patient. The ADA and EASD have requested an update to the position statement incorporating new data from recent clinical trials. Between June and September of 2014, the Writing Group reconvened, including one face-to-face meeting, to discuss the changes. An entirely new statement was felt to be unnecessary. Instead, the group focused on those areas where revisions were suggested by a changing evidence base. This briefer article should therefore be read as an addendum to the previous full account (1,2). Glucose control remains a major focus in the management of patients with type 2 diabetes. However, this should always be in the context of a comprehensive cardiovascular risk factor reduction program, to include smoking cessation and the adoption of other healthy lifestyle habits, blood pressure control, lipid management with priority to statin medications, and, in some circumstances, antiplatelet therapy. Studies have conclusively determined that reducing hyperglycemia decreases the onset and progression of …

Integrity signals

Registry

Crossref · 10.2337/dc14-2441

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07037-8 · Cited by 8,247
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citation
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Self-citation
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Self-citation
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Self-citation

Show all 68 references

Sorted by citations

Items 901–1,000 of 1,014

A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges
King, A. B., Philis‐Tsimikas, A., Kilpatrick, E. S., Langbakke, I. H., Begtrup, K., & Vilsbøll, T. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0405 · Cited by 27
Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials
Orme, M. E., Nguyen, H. P., Lu, J., & Thomas, S. V. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s116810 · Cited by 27
Cardioprotective potential of N-acetyl cysteine against hyperglycaemia-induced oxidative damage: a protocol for a systematic review
Dludla, P. V., Nkambule, B. B., Dias, S. C., & Johnson, R. (2017) · Systematic Reviews · doi:10.1186/s13643-017-0493-8 · Cited by 27
Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus
Budoff, M. J., & Wilding, J. P. H. (2017) · International Journal of Clinical Practice · doi:10.1111/ijcp.12948 · Cited by 27
Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy
Goldenberg, R., & Berard, L. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1372118 · Cited by 27
Automated Insulin Delivery Systems as a Treatment for Type 2 Diabetes Mellitus: A Review
Karol, A. B., O’Malley, G., Fallurin, R., & Levy, C. J. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.10.001 · Cited by 27
Triple fixed drug combinations in type 2 diabetes
John, M., Gopinath, D., & Kalra, S. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.152739 · Cited by 27
Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase‐4 inhibitor, in K orean patients with type 2 diabetes mellitus: a 24‐week multicentre, randomized, double‐blind, placebo‐controlled phase III trial
Hong, S., Park, C. ‐., Han, K. A., Chung, C. H., Ku, B. J., Jang, H.-C., Ahn, C. W., Lee, M. ‐., Moon, M. K., Son, H. S., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12631 · Cited by 27
Dulaglutide (LY-2189265) for the treatment of type 2 diabetes
Scheen, A. J. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1141046 · Cited by 27
A socioeconomic and behavioral survey of patients with difficult-to-control type 2 diabetes mellitus reveals an association between diabetic retinopathy and educational attainment
Emoto, N., Okajima, F., Sugihara, H., & Goto, R. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s116198 · Cited by 27
Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1258401 · Cited by 27
Non-insulin anti-diabetic drugs: An update on pharmacological interactions
Ruscica, M., Baldessin, L., Boccia, D., Racagni, G., & Mitro, N. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.11.005 · Cited by 27
Association of Genomic Instability with HbA1c levels and Medication in Diabetic Patients
Grindel, A., Brath, H., Nersesyan, A. K., Knasmüller, S., & Wagner, K. (2017) · Scientific Reports · doi:10.1038/srep41985 · Cited by 27
Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control
Villar, M. M.-D., Martínez‐Abundis, E., Preciado-Márquez, R. O., & González-Ortíz, M. (2017) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000242 · Cited by 27
Short‐term intensive insulin therapy could be the preferred option for new onset T ype 2 diabetes mellitus patients with HbA1c > 9%
Weng, J. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12581 · Cited by 27
Lactate Levels with Chronic Metformin Use: A Narrative Review
Huang, W., Castelino, R. L., & Peterson, G. M. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0564-6 · Cited by 27
Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis
Sharma, M., Beckley‐Hoelscher, N., Nazareth, I., & Petersen, I. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-017260 · Cited by 27
Sustained 52‐week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes
Handelsman, Y., Mathieu, C., Prato, S. D., JOHNSSON, E. K., Kurlyandskaya, R., Iqbal, N., García‐Sánchez, R., & Rosenstock, J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13594 · Cited by 27
Triple therapy with low‐dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes
Rosenstock, J., Perl, S., JOHNSSON, E. K., García‐Sánchez, R., & Jacob, S. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13795 · Cited by 27
Diabetes, dysglycemia, and vascular surgery
Duwayri, Y. M., & Jordan, W. D. (2019) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2019.05.027 · Cited by 27
Benefit of Digital Tools Used for Integrated Personalized Diabetes Management: Results From the PDM-ProValue Study Program
Heinemann, L., Schramm, W., Koenig, H., Moritz, A., Vesper, I., Weissmann, J., & Kulzer, B. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819867686 · Cited by 27
Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonist’s role intreatment; from the past to future
Doğruel, H., & Balcı, M. K. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i8.446 · Cited by 27
Treatment patterns of drug-naive patients with type 2 diabetes mellitus: a retrospective cohort study using a Japanese hospital database
Morita, Y., Murayama, H., Odawara, M., & Bauer, M. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0486-y · Cited by 27
Glucose Lowering Treatment Modalities of Type 2 Diabetes Mellitus
Canpolat, A. G., & Şahin, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_516 · Cited by 27
Patient Preferences for Medications in Managing Type 2 Diabetes Mellitus: A Discrete Choice Experiment
Özdemir, S., Baid, D., Verghese, N. R., Lam, A. Y. R., Lee, P. C., Lim, A. Y., Zhu, L., Ganguly, S., Finkelstein, E. A., & Goh, S. (2020) · Value in Health · doi:10.1016/j.jval.2020.01.023 · Cited by 27
Noninvasive blood glucose monitor via multi-sensor fusion and its clinical evaluation
Feng, R., Geng, Z., Li, A., Chu, Y., Wu, C., Zhang, N., Guo, X., Zhang, J., Wang, X., & Tang, F. (2021) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2021.129445 · Cited by 27
Explaining psychological insulin resistance in adults with non-insulin-treated type 2 diabetes: The roles of diabetes distress and current medication concerns. Results from Diabetes MILES—Australia
Holmes‐Truscott, E., Skinner, T. C., Pouwer, F., & Speight, J. (2015) · Primary care diabetes · doi:10.1016/j.pcd.2015.06.006 · Cited by 27
Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes
Hadefi, A., Huberty, V., Lemmers, A., Arvanitakis, M., Maggs, D., Costamagna, G., & Devière, J. (2018) · Digestive Diseases · doi:10.1159/000487078 · Cited by 26
Effects of exenatide versus insulin glargine on body composition in overweight and obese T2DM patients: a randomized controlled trial
Yin, T.-T., Bi, Y., Li, P., Shen, S.-M., Wang, W.-M., Jiang, C., Gao, C.-X., Wang, Y., Gao, L.-J., Zhu, D.-L., et al. (2018) · Nutrition & Metabolism · doi:10.1186/s12986-018-0295-6 · Cited by 26
Improving medication adherence in type 2 diabetes: strategies for better clinical and economic outcomes
HIGHTON, P. J., Funnell, M. P., Gupta, P., Zaccardi, F., Lim, L., Seidu, S., & Khunti, K. (2025) · Diabetologia · doi:10.1007/s00125-025-06617-x · Cited by 26
Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes
Christiansen, J. S., NISKANEN, L. K., Rasmussen, S., Johansen, T., & Fulcher, G. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12355 · Cited by 26
Patients' with type 2 diabetes willingness to pay for insulin therapy and clinical outcomes
Feher, M. D., Brazier, J. E., Schaper, N. C., Vega-Hernandez, G., Nikolajsen, A., & Bøgelund, M. (2016) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000192 · Cited by 26
A Novel Index Using Soluble CD36 Is Associated with the Prevalence of Type 2 Diabetes Mellitus: Comparison Study with Triglyceride-Glucose Index
Kim, H. J., Moon, J. S., Park, I. R., Kim, J. H., Yoon, J. S., Won, K. C., & Lee, H. W. (2017) · Endocrinology and Metabolism · doi:10.3803/enm.2017.32.3.375 · Cited by 26
Racial differences in performance of HbA1c for the classification of diabetes and prediabetes among US adults of non‐Hispanic black and white race
Ford, C. N., Leet, R. W., Kipling, L. M., Rhee, M. K., Jackson, S. L., Wilson, P. W. F., Phillips, L. S., & Staimez, L. R. (2019) · Diabetic Medicine · doi:10.1111/dme.13979 · Cited by 26
Egyptian consensus on treat-to-target approach for osteoporosis: a clinical practice guideline from the Egyptian Academy of bone health and metabolic bone diseases
Miedany, Y. M. E., Abu-Zaid, M. H., Gaafary, M. M. E., Naby, M. M. H. E., Fathi, N. A., Saber, H. G., Hassan, W. A., Eissa, M., Mohannad, N., Khaled, H. F., et al. (2021) · Egyptian Rheumatology and Rehabilitation · doi:10.1186/s43166-020-00056-9 · Cited by 26
Targeting Myotonic Dystrophy Type 1 with Metformin
García-Puga, M., Saenz‐Antoñanzas, A., Matheu, A., & de Munaín, A. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052901 · Cited by 26
Beneficial effect of farnesoid X receptor activation on metabolism in a diabetic rat model
Zhang, H., Wang, X., WU, Z.-H., LIU, H.-L., Chen, W., ZHANG, Z.-Z., Chen, D., & Zeng, T. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.4761 · Cited by 26
Metformin Inhibits Migration and Invasion of Cholangiocarcinoma Cells
Trinh, S. X., Nguyen, H., Saimuang, K., Prachayasittikul, V., & Chan-on, W. (2017) · Europe PMC (PubMed Central) · doi:10.22034/apjcp.2017.18.2.473 · Cited by 26
Treatment patterns and clinical characteristics of patients with type 2 diabetes mellitus according to body mass index: findings from an electronic medical records database
Weng, W., Tian, Y., Kimball, E. S., Kong, S. X., Bouchard, J. R., Hobbs, T. M., & Sakurada, B. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000382 · Cited by 26
Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study
On behalf of the NN2211-4118 Study Group, Lapolla, A., Berra, C., Boemi, M., Bossi, A. C., Candido, R., Cianni, G. D., Frontoni, S., Genovese, S., Ponzani, P., et al. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0652-2 · Cited by 26
American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Testing for Autonomic And Somatic Nerve Dysfunction
Vinik, A. I., Camacho, P. M., Davidson, J. A., Handelsman, Y., Lando, H. M., Leddy, A. L., Reddy, S. K., Cook, R., Spallone, V., Tesfaye, S. H., et al. (2017) · Endocrine Practice · doi:10.4158/ep-2017-0053 · Cited by 26
Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study
Gupta, S., Wang, H., SKOLNIK, N., Tong, L., Liebert, R., Lee, L. K., Stella, P., Cali, A. M. G., & Preblick, R. (2018) · Advances in Therapy · doi:10.1007/s12325-017-0651-3 · Cited by 26
Mechanisms of beneficial effects of metformin on fatty acid-treated human islets
Cen, J., Sargsyan, E., Forslund, A. H., & Bergsten, P. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-17-0304 · Cited by 26
Valsartan prevents glycerol-induced acute kidney injury in male albino rats by downregulating TLR4 and NF-κB expression
Sun, X., Luan, Q., & Qiu, S. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.07.149 · Cited by 26
Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis
Qian, D., Zhang, T., Tan, X., Zheng, P., Liang, Z., Xie, J., Jiang, J., & Situ, B. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202563 · Cited by 26
A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus
Shestakova, M. V., Wilding, J. P. H., Wilpshaar, W., Tretter, R., Orlova, V. L., & Verbovoy, A. F. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.10.018 · Cited by 26
Pharmacoeconomic evaluation of sodium-glucose transporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes
Rahman, W., Solinsky, P. J., Munir, K. M., & Lamos, E. M. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1543408 · Cited by 26
TMG-123, a novel glucokinase activator, exerts durable effects on hyperglycemia without increasing triglyceride in diabetic animal models
Tsumura, Y., Tsushima, Y., Tamura, A., Hasebe, M., Kanou, M., Kato, H., & Kobayashi, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172252 · Cited by 26
Lack of effect of the SLC47A1 and SLC47A2 gene polymorphisms on the glycemic response to metformin in type 2 diabetes mellitus patients
Raj, G. M., Mathaiyan, J., Wyawahare, M., & Priyadarshini, R. (2018) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmpt-2018-0030 · Cited by 26
Acarbose add-on therapy in patients with type 2 diabetes mellitus with metformin and sitagliptin failure: A multicenter, randomized, double-blind, placebo-controlled study
Yang, H. K., Lee, S.-H., Shin, J., Choi, Y.-H., Ahn, Y.-B., Lee, B.-W., Rhee, E. J., Min, K. W., & Yoon, K.-H. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0054 · Cited by 25
Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus
Giorgino, F., Caruso, I., & Napoli, R. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108478 · Cited by 24
Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine
Ott, C., Jung, S., Korn, M., Kannenkeril, D., Bosch, A., Kolwelter, J., Striepe, K., Bramlage, P., Schiffer, M., & Schmieder, R. E. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01358-8 · Cited by 25
Combination of mulberry leaf active components possessed synergetic effect on SD rats with diabetic nephropathy by mediating metabolism, Wnt/β-catenin and TGF-β/Smads signaling pathway
Ji, T., Wang, J., Xu, Z., Cai, H.-D., Su, S., Peng, X. X., & Hong-sheng, R. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115026 · Cited by 25
Artemisia abrotanum and Symphytum officinale Polyphenolic Compounds-Rich Extracts with Potential Application in Diabetes Management
Neagu, E., Păun, G., Albu, C., Eremia, S. A. V., & Radu, G. L. (2023) · Metabolites · doi:10.3390/metabo13030354 · Cited by 25
Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes
Muscelli, E., Astiarraga, B., Barsotti, E., Mari, A., Schliess, F., Nosek, L., Heise, T., Broedl, U. C., Woerle, H., & Ferrannini, E. (2015) · Diabetologia · doi:10.1007/s00125-015-3845-8 · Cited by 25
Self-citation
Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors
Htoo, P. T., Buse, J. B., Gokhale, M., Marquis, M. A., Pate, V., & Stürmer‎, T. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2068-3 · Cited by 25
Self-citation
The efficacy and safety of liraglutide added to metformin in patients with diabetes: a meta-analysis of randomized controlled trials
Gu, J., Xin, M., Guo, Y. P., Wang, L., Zheng, H., Liu, Y., Wu, B., & Wang, D. (2016) · Scientific Reports · doi:10.1038/srep32714 · Cited by 25
Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health
Egger, A., KRAENZLIN, M. E., & Meier, C. (2016) · Current Osteoporosis Reports · doi:10.1007/s11914-016-0337-9 · Cited by 25
Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease
Zonszein, J., & Groop, P. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0208-5 · Cited by 25
Efficacy and safety of fixed‐dose combination therapy, alogliptin plus metformin, in A sian patients with type 2 diabetes: A phase 3 trial
Ji, L., Li, L., Kuang, J., Yang, T., Kim, D., Kadir, A. A., Huang, C., & Lee, D. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12875 · Cited by 25
Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials
Åhrén, B., Carr, M. C., Murphy, K., Perkins, C., Rendell, M., Mallory, J. M., Wilson, T. H., & JOHNSON, S. L. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.02.017 · Cited by 25
Risk factors for unstable blood glucose level: integrative review of the risk factors related to the nursing diagnosis
Teixeira, A. M., Tsukamoto, R., Lopes, C. T., & Silva, R. D. C. G. E. (2017) · Revista Latino-Americana de Enfermagem · doi:10.1590/1518-8345.1688.2893 · Cited by 25
Renal outcomes with dipeptidyl peptidase-4 inhibitors
Scheen, A. J., & Delanaye, P. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.07.011 · Cited by 25
Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States
Neslusan, C. A., Teschemaker, A. R., Willis, M. S., Johansen, P., & Vo, L. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0371-y · Cited by 25
Fibroblast growth factor 21 regulates glucose metabolism in part by reducing renal glucose reabsorption
Li, S., Wang, N., Guo, X., Li, J., Zhang, T., Ren, G., & Li, D. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.09.078 · Cited by 25
A Glimepiride-Metformin Multidrug Crystal: Synthesis, Crystal Structure Analysis, and Physicochemical Properties
Bian, X., Jiang, L., Gan, Z., Guan, X., Zhang, L., Cai, L., & Hu, X. (2019) · Molecules · doi:10.3390/molecules24203786 · Cited by 25
Lysophosphatidylcholine Containing Anisic Acid Is Able to Stimulate Insulin Secretion Targeting G Protein Coupled Receptors
Drzazga, A. K., Okulus, M., Rychlicka, M., Biegała, Ł., Gliszczyńska, A., & Gendaszewska‐Darmach, E. (2020) · Nutrients · doi:10.3390/nu12041173 · Cited by 25
DIA-DB: A Database and Web Server for the Prediction of Diabetes Drugs
Pérez‐Sánchez, H., den-Haan, H., Peña-García, J. J., Lozano‐Sánchez, J., Moreno, M. E. M., Sánchez-Pérez, A., Muñoz, A., Ruiz-Espinosa, P., Pereira, A. S. P., Katsikoudi, A., et al. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00107 · Cited by 25
Sulfonylureas use and fractures risk in elderly patients with type 2 diabetes mellitus: a meta-analysis study
Tao, Y., Meng, E., Shi, J., & Zhang, Z. (2020) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01736-4 · Cited by 25
Long-term cost-effectiveness of two GLP-1 receptor agonists for the treatment of type 2 diabetes mellitus in the Italian setting: Liraglutide versus lixisenatide
Hunt, B., Kragh, N., McConnachie, C. C., Valentine, W. J., Rossi, M. C., & Montagnoli, R. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.05.354 · Cited by 24
Glucose: Archetypal Biomarker in Diabetes Diagnosis, Clinical Management and Research
Krentz, A. J., & Hompesch, M. (2016) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0170 · Cited by 24
Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease
Emdin, C. A., Klarin, D. M., Natarajan, P., Florez, J. C., Kathiresan, S., & Khera, A. V. (2017) · Diabetes · doi:10.2337/db17-0149 · Cited by 24
The impact of online self-management interventions on midlife adults with type 2 diabetes: a systematic review
Celik, A., Forde, R., & Sturt, J. A. (2020) · British Journal of Nursing · doi:10.12968/bjon.2020.29.5.266 · Cited by 24
Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?
Davies, M. J., Bianchi, C., & Prato, S. D. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154242 · Cited by 24
Early combination versus initial metformin monotherapy in the management of newly diagnosed type 2 diabetes: An East Asian perspective
Ji, L., Chan, J. C. N., Yu, M., Yoon, K., Kim, S. G., Choi, S. H., Huang, C., Tu, S., Wang, C., Paldánius, P. M., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14205 · Cited by 24
Results of a multidisciplinary strategy to improve the management of cardiovascular risk factors after liver transplantation
Sastre, L., Garcı́a, R., Viñals, C., Amor, A. J., Yago, G., Hervás, A., Sánchez, L., Trabal, J., Molero, J., Escudé, L., et al. (2022) · Liver Transplantation · doi:10.1002/lt.26443 · Cited by 24
Recent advancements on novel approaches of insulin delivery
Karmakar, S., Bhowmik, M., Laha, B., & Manna, S. (2023) · Medicine in Novel Technology and Devices · doi:10.1016/j.medntd.2023.100253 · Cited by 24
Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy’s safety profile
Schwartz, S. S., Jellinger, P. S., & Herman, M. E. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1191955 · Cited by 24
Omarigliptin for the treatment of type 2 diabetes
Tan, X. (2016) · Endocrine · doi:10.1007/s12020-016-1011-9 · Cited by 24
Treatment of Type 2 Diabetes: From “Guidelines” to “Position Statements” and Back
Mosenzon, O., Pollack, R. M., & Raz, I. (2016) · Diabetes Care · doi:10.2337/dcs15-3003 · Cited by 24
Gal3 Links Inflammation and Insulin Resistance
Siwicki, M. R., Engblom, C., & Pittet, M. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.10.014 · Cited by 24
Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial
Li, F.-F., Jiang, L., Fu, L., Zhu, H., Zhou, P., Zhang, D., Su, X., Wu, J.-D., Ye, L., & Ma, J. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0222-7 · Cited by 24
Preventing cardiovascular disease in older adults: One size does not fit all
Orkaby, A. R., Onuma, O. K., Qazi, S., Gaziano, J. M., & Driver, J. A. (2018) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.85a.16119 · Cited by 24
Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3)
Dahlqvist, S., Ahlén, E., Filipsson, K., Gustafsson, T. P., Hirsch, I. B., Tuomilehto, J., Imberg, H., Åhrén, B., Attvall, S., & Lind, M. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000464 · Cited by 24
iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes
Hinnen, D., & Strong, J. L. (2018) · Diabetes Spectrum · doi:10.2337/ds17-0014 · Cited by 24
Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme
DeVries, J. H., Desouza, C. V., Bellary, S., Unger, J. R., HANSEN, O. K. H., Zacho, J., & Woo, V. C. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13396 · Cited by 24
Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study
Bellido, V., Padín, C. A., Catarig, A., Clark, A., Pittol, S. B., & Delgado, E. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11174938 · Cited by 24
Management of Type 2 Diabetes
Rudy Bilous MD, F., Donnelly, R., & Iskandar Idris DM, F. (2002) · Wiley eBooks · doi:10.1002/9781118976074.ch11 · Cited by 24
Analytical tools for determination of new oral antidiabetic drugs, glitazones, gliptins, gliflozins and glinides, in bulk materials, pharmaceuticals and biological samples
Gumieniczek, A., & Berecka-Rycerz, A. (2016) · Open Chemistry · doi:10.1515/chem-2016-0023 · Cited by 24
Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis
Liakopoulou, P., Liakos, A., Vasilakou, D., Athanasiadou, E. A., Bekiari, E., Kazakos, K., & Τσάπας, Α. (2017) · Endocrine · doi:10.1007/s12020-017-1293-6 · Cited by 24
Severe hypoglycaemia among patients with type 2 diabetes requiring emergency hospital admission: T he H ypoglycaemia I n P ortugal O bservational S tudy– E mergency R oom ( HIPOS – ER )
Conceição, J., Dores, J. M., Araújo, F., Laires, P. A., Carr, R. D., Brodovicz, K. G., Radican, L., & Nogueira, A. M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13030 · Cited by 24
Complex interplay between metformin, AKI and lactic acidosis
Rhee, C. M., & Kalantar‐Zadeh, K. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.105 · Cited by 24
Predictors of glycemic control and diabetes-related costs among type 2 diabetes patients initiating therapy with liraglutide in the United States
Durden, E., Lenhart, G., Lopez-Gonzalez, L., Hammer, M., & Langer, J. (2016) · Journal of Medical Economics · doi:10.3111/13696998.2015.1131703 · Cited by 23
Initiation of human regular U-500 insulin use is associated with improved glycemic control: a real-world US cohort study
Eby, E. L., Curtis, B. H., Gelwicks, S., Hood, R. C., IDRIS, I. R., Peters, A. L., Bergenstal, R. M., & Jackson, J. A. (2015) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2014-000074 · Cited by 23
Self-citation
Pharmacological management of type 2 diabetes: what’s new in 2017?
Scheen, A. J. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1376652 · Cited by 23
Insulin Monotherapy Versus Insulin Combined with Other Glucose-Lowering Agents in Type 2 Diabetes: A Narrative Review
Abdi, H., Azizi, F., & Amouzegar, A. (2018) · Intern J Endocrinol Metab · doi:10.5812/ijem.65600 · Cited by 23
Second-generation Insulin Analogues – a Review of Recent Real-world Data and Forthcoming Head-to-head Comparisons
Mauricio, D., & HRAMIAK, I. M. (2018) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2018.14supp1.2 · Cited by 23
Sodium‐Glucose Cotransporter‐2 Inhibitors and Cardiovascular Protection Among Patients With Type 2 Diabetes Mellitus: A Systematic Review
Yankah, R. K., Anku, E. K., & Eligar, V. S. (2024) · Journal of Diabetes Research · doi:10.1155/2024/9985836 · Cited by 23
Impact of coffee and its bioactive compounds on the risks of type 2 diabetes and its complications: A comprehensive review
Mohamed, A. I., Erukainure, O. L., Salau, V. F., & Islam, M. S. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103075 · Cited by 23
Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus
Barnett, A. H., Charbonnel, B. H., Moses, R. G., & Kalra, S. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1081589 · Cited by 23

Authors: Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R.
Affiliations: Yale New Haven Hospital (US)
Park Nicollet Health Services (US)
University of North Carolina at Chapel Hill (US)
Diabetes Center/Department of Internal Medicine, VU University Medical Center, Amsterdam, the Netherlands
University of Pisa (IT)
Diabeteszentrum Bad Lauterberg (DE)
University of Southern California (US)
Second Medical Department, Aristotle University Thessaloniki, Thessaloniki, Greece
American Cancer Society (US)
Churchill Hospital (GB)
Corresponding author: Inzucchi, Silvio E.
ORCID: Inzucchi, Silvio E.
Bergenstal, Richard M.
Buse, John B.
Ferrannini, Ele
Nauck, Michael
Peters, Anne L.
Wender, Richard
Matthews, David R.
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2014-12-13
Volume: 38
Issue: 1
Pages: 140-149
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/dc14-2441
OpenAlex: W2160088494
Cited by: 3,066
References: 68
Citations by year: 2026: 52 · 2025: 84 · 2024: 96 · 2023: 135 · 2022: 138 · 2021: 142 · 2020: 202 · 2019: 313 · 2018: 482 · 2017: 545 · 2016: 540 · 2015: 325 · 2014: 7
FWCI: 380.40
Type: journal article
Language: en
Open access: green
pure.amsterdamumc.nl
Licence: other-oa
Locations: Diabetes Care (publishedVersion)
PubMed (publishedVersion)
Pure Amsterdam UMC (publishedVersion, other-oa)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Funders: Bristol-Myers Squibb
Eli Lilly and Company
AstraZeneca
GlaxoSmithKline
Sanofi
Massachusetts General Hospital
Yale University
Kaiser Permanente
F. Hoffmann-La Roche
Case Western Reserve University
School of Medicine, Case Western Reserve University
Intarcia Therapeutics
National Institute for Health and Care Research
University of Sydney
Universiteit van Amsterdam
University of Toronto
Novo Nordisk
Uniwersytet Łódzki
European Association for the Study of Diabetes
Université de Nantes
Servier
Lilly Deutschland
University of Ioannina
School of Medicine, University of Kansas
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: type 2 diabetes, hyperglycemia management, antidiabetic drugs, patient-centered care, shared decision-making, glucose-lowering agents, cardiovascular risk reduction, smoking cessation, blood pressure control, lipid control, statins, antiplatelet therapy, lifestyle modification
MeSH terms: Clinical Trials as Topic, Diabetes Mellitus, Type 2, Drug Combinations, Humans, Hyperglycemia, Metformin, United States, Disease Management, Glycemic Index, Thiazolidinediones, Dipeptidyl-Peptidase IV Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks